Tag Archive for: biopharmaceutical

Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference

Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announced that Amir Hefni, Ph.D., Chief Executive Officer, and Simon Ramsden, Chief Financial Officer, will participate in meetings with investors at the […]

Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Market opportunity estimated to be greater than US$1 billion Key highlights –      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model –      Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS –      Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced […]

Poolbeg Pharma Plc – Board Appointment

24 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee. Read more…

Breye Therapeutics Strengthens Management Team and Launches Website

Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page. Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of […]

Positive Initial Data Analysis in POLB 001 LPS Challenge Trial

Early data read out indicates a successful LPS human challenge trial Key Highlights ·      POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo ·      A clear dose-response relationship was demonstrated                                                                 ·      Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported ·      Full […]